1. Home
  2. BBCP vs DCTH Comparison

BBCP vs DCTH Comparison

Compare BBCP & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concrete Pumping Holdings Inc.

BBCP

Concrete Pumping Holdings Inc.

HOLD

Current Price

$7.08

Market Cap

333.0M

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$10.01

Market Cap

289.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBCP
DCTH
Founded
1983
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Engineering & Construction
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
333.0M
289.2M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
BBCP
DCTH
Price
$7.08
$10.01
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$7.50
$22.60
AVG Volume (30 Days)
110.1K
748.8K
Earning Date
01-07-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.16
0.03
Revenue
$395,562,000.00
$79,603,000.00
Revenue This Year
N/A
$131.97
Revenue Next Year
$1.28
$38.84
P/E Ratio
$42.80
$300.53
Revenue Growth
N/A
251.54
52 Week Low
$4.78
$8.12
52 Week High
$9.68
$18.23

Technical Indicators

Market Signals
Indicator
BBCP
DCTH
Relative Strength Index (RSI) 66.24 54.58
Support Level $6.29 $9.59
Resistance Level $6.92 $10.65
Average True Range (ATR) 0.33 0.45
MACD 0.09 0.10
Stochastic Oscillator 83.90 54.67

Price Performance

Historical Comparison
BBCP
DCTH

About BBCP Concrete Pumping Holdings Inc.

Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators position it to deliver concrete placement solutions. The company's operating segment includes U.S. Concrete Pumping; U.K. Operations; U.S. Concrete Waste Management Services and Corporate. It generates maximum revenue from the U.S. Concrete Pumping segment. Geographically, it generates majority of the revenue from its business in United States.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: